↓ Skip to main content

Combination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections

Overview of attention for article published in Seminars in Respiratory & Critical Care Medicine, February 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (57th percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
117 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Combination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections
Published in
Seminars in Respiratory & Critical Care Medicine, February 2015
DOI 10.1055/s-0034-1396906
Pubmed ID
Authors

J. Davis, S. Hal, S. Tong

Abstract

Outcomes from methicillin-resistant Staphylococcus aureus (MRSA) infections are relatively poor, at least in part due to the limitations of vancomycin (the current standard treatment for MRSA). Combination antibiotic treatment for MRSA infections is an attractive alternative as it could address most of vancomycin's shortcomings, including poor tissue penetration, slow bacterial killing, and emerging resistance in some strains of MRSA. However, the theoretical promise of combination therapy for MRSA infections has not been borne out in most in vitro and animal studies. Multiple combinations have been tested and have been either antagonistic, indifferent, or have had conflicting findings in various studies. This includes combinations of two primarily active agents (such as vancomycin plus daptomycin or linezolid), or the addition of gentamicin or rifampin to either vancomycin or daptomycin. However, hope on this front has come from an unexpected quarter. Although MRSA is by definition inherently resistant to nearly all β-lactam antibiotics, this class of drugs has consistently shown evidence of synergy with either daptomycin or vancomycin in over 25 separate in vitro studies, and a limited number of animal and human observational studies. However, there are currently insufficient data to recommend β-lactam combination therapy in routine clinical use. Results of current and planned randomized controlled trials of this strategy are awaited.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Czechia 1 <1%
Argentina 1 <1%
Brazil 1 <1%
Unknown 113 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 20 17%
Researcher 16 14%
Student > Ph. D. Student 13 11%
Student > Master 11 9%
Student > Postgraduate 10 9%
Other 23 20%
Unknown 24 21%
Readers by discipline Count As %
Medicine and Dentistry 38 32%
Immunology and Microbiology 15 13%
Biochemistry, Genetics and Molecular Biology 15 13%
Agricultural and Biological Sciences 9 8%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Other 3 3%
Unknown 31 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2020.
All research outputs
#10,369,983
of 18,812,670 outputs
Outputs from Seminars in Respiratory & Critical Care Medicine
#242
of 543 outputs
Outputs of similar age
#127,319
of 304,150 outputs
Outputs of similar age from Seminars in Respiratory & Critical Care Medicine
#3
of 12 outputs
Altmetric has tracked 18,812,670 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 543 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,150 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.